• 1. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 2. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 3. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 4. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 5. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Introduction to 2-((tert-Butoxycarbonyl)amino)-3,3-dimethylbutanoic acid (CAS No. 102185-35-3)

2-((tert-Butoxycarbonyl)amino)-3,3-dimethylbutanoic acid, identified by the Chemical Abstracts Service Number (CAS No.) 102185-35-3, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and biotechnology. This compound, featuring a unique structural configuration, serves as a crucial intermediate in the synthesis of various bioactive molecules. Its molecular structure incorporates a tert-butoxycarbonyl (Boc) protecting group and a 3,3-dimethylbutanoic acid backbone, which endows it with distinct chemical properties and reactivity patterns. These characteristics make it particularly valuable in the development of peptide mimetics, protease inhibitors, and other therapeutic agents.

The Boc group is a widely employed protective group in peptide synthesis, known for its stability under basic conditions and ease of removal under acidic conditions. This feature allows for precise control over the synthetic pathway, enabling chemists to construct complex peptide structures with high fidelity. The presence of the dimethyl substitution at the C3 position enhances the compound's steric hindrance, which can be strategically exploited to modulate enzyme binding affinities or improve metabolic stability in drug candidates.

In recent years, there has been a surge in research focused on developing novel inhibitors targeting various therapeutic pathways. Among these, proteases play a pivotal role in numerous biological processes, including inflammation, blood clotting, and cancer progression. 2-((tert-Butoxycarbonyl)amino)-3,3-dimethylbutanoic acid has been explored as a key building block in the design of protease inhibitors due to its ability to mimic natural substrates while incorporating pharmacophoric elements that enhance binding specificity. For instance, studies have demonstrated its utility in synthesizing inhibitors of matrix metalloproteinases (MMPs), which are implicated in tumor invasion and metastasis.

Advances in computational chemistry and molecular modeling have further accelerated the discovery of novel drug candidates derived from this compound. By leveraging high-throughput screening and structure-based drug design approaches, researchers have identified derivatives of 2-((tert-Butoxycarbonyl)amino)-3,3-dimethylbutanoic acid that exhibit potent activity against target enzymes. These derivatives often feature modifications such as altered side chains or additional functional groups designed to optimize pharmacokinetic properties and reduce off-target effects.

The pharmaceutical industry has also shown interest in this compound for its potential applications in peptide drug development. Peptide-based therapeutics are increasingly recognized for their specificity and efficacy in treating diseases such as diabetes, autoimmune disorders, and cancer. However, the inherent instability of peptides necessitates the use of protecting groups like the Boc moiety to ensure their integrity during synthesis and formulation. The structural features of 2-((tert-Butoxycarbonyl)amino)-3,3-dimethylbutanoic acid make it an ideal candidate for generating advanced peptide mimetics that can bypass some of the limitations associated with traditional peptide-based drugs.

Recent studies have highlighted the compound's role in developing next-generation biologics with improved pharmacological profiles. For example, researchers have utilized derivatives of this compound to create cyclic peptides that exhibit enhanced resistance to enzymatic degradation while maintaining biological activity. Such innovations are critical for expanding the therapeutic potential of peptide drugs and improving patient outcomes.

The synthesis of 2-((tert-Butoxycarbonyl)amino)-3,3-dimethylbutanoic acid typically involves multi-step organic reactions starting from readily available precursors. Key synthetic steps include Boc protection of an amine group followed by alkylation at the C3 position to introduce the dimethyl groups. The use of catalytic methods and green chemistry principles has further refined these synthetic routes, making them more efficient and environmentally sustainable.

In conclusion,2-((tert-Butoxycarbonyl)amino)-3,3-dimethylbutanoic acid (CAS No. 102185-35-3) represents a versatile intermediate with significant applications in pharmaceutical research and drug development. Its unique structural features and reactivity patterns make it indispensable for constructing complex bioactive molecules, particularly protease inhibitors and peptide mimetics. As research continues to uncover new therapeutic targets and innovative synthetic strategies,this compound is poised to remain at the forefront of medicinal chemistry innovation.

• 2419-94-5(N-Boc-L-glutamic acid)
• 53308-95-5(Boc-Nva-OH)
• 13139-16-7(Boc-L-Ile-OH)
• 16937-99-8((tert-Butoxycarbonyl)-D-leucine)
• 13139-15-6(Boc-L-Leu-OH)
• 62965-35-9(N-Boc-L-tert-Leucine)
• 70491-05-3(Boc-D-Chg-OH)
• 13726-67-5(Boc-Asp-OH)
• 13734-28-6(Boc-Lys-OH)
• 41088-86-2(Boc-L-Homoserine)